Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Inks microRNA Drugs Collaboration with AstraZeneca

Premium

Regulus Therapeutics this week announced that it has formed a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics against three exclusive targets.

The preclinical targets, Regulus said, are focused on cardiovascular and metabolic diseases and cancer. The company said its work on miR-33 for the treatment of atherosclerosis is included in the arrangement.

Regulus acquired the exclusive rights to miR-33-related intellectual property early last year (GSN 3/31/2011). Notably, miRNA drug firm Santaris Pharma is also developing miR-33-targeting therapies for cardiovascular disorders with its own IP (GSN 3/3/2011).

AstraZeneca will make an initial $28 million payment to Regulus, which includes an equity investment. Regulus also stands to receive milestones and royalties.

Regulus will be responsible for preclinical development of the drugs, while AstraZeneca will handle clinical and commercialization efforts.

Additional terms were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.